Stem Cell Therapy for Neuromuscular Diseases | InTechOpen
Posted: March 31, 2015 at 2:44 am
1. Introduction
Neuromuscular disease is a very broad term that encompasses many diseases and aliments that either directly, via intrinsic muscle pathology, or indirectly, via nerve pathology, impair the functioning of the muscles. Neuromuscular diseases affect the muscles and/or their nervous control and lead to problems with movement. Many are genetic; sometimes, an immune system disorder can cause them. As they have no cure, the aim of clinical treatment is to improve symptoms, increase mobility and lengthen life. Some of them affect the anterior horn cell, and are classified as acquired (e.g. poliomyelitis) and hereditary (e.g. spinal muscular atrophy) diseases. SMA is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. As a consequence of the lost of the neurons, muscles weakness becomes to be evident, affecting walking, crawling, breathing, swallowing and head and neck control. Neuropathies affect the peripheral nerve and are divided into demyelinating (e.g. leucodystrophies) and axonal (e.g. porphyria) diseases. Charcot-Marie-Tooth (CMT) is the most frequent hereditary form among the neuropathies and its characterized by a wide range of symptoms so that CMT-1a is classified as demyelinating and CMT-2 as axonal (Marchesi & Pareyson, 2010). Defects in neuromuscular junctions cause infantile and non-infantile Botulism and Myasthenia Gravis (MG). MG is a antibody-mediated autoimmune disorder of the neuromuscular junction (NMJ) (Drachman, 1994; Meriggioli & Sanders, 2009). In most cases, it is caused by pathogenic autoantibodies directed towards the skeletal muscle acetylcholine receptor (AChR) (Patrick & Lindstrom, 1973) while in others, non-AChR components of the postsynaptic muscle endplate, such as the muscle-specific receptor tyrosine kinase (MUSK), might serve as targets for the autoimmune attack (Hoch et al., 2001). Although the precise origin of the autoimmune response in MG is not known, genetic predisposition and abnormalities of the thymus gland such as hyperplasia and neoplasia could have an important role in the onset of the disease (Berrih et al., 1984; Roxanis et al., 2001).
Several diseases affect muscles: they are classified as acquired (e.g. dermatomyositis and polymyositis) and hereditary (e.g. myotonic disorders and myopaties) forms. Among the myopaties, muscular dystrophies are characterized by the primary wasting of skeletal muscle, caused by mutations in the proteins that form the link between the cytoskeleton and the basal lamina (Cossu & Sampaolesi, 2007). Mutations in the dystrophin gene cause severe form of hereditary muscular diseases; the most common are Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). DMD patients suffer for complete lack of dystrophin that causes progressive degeneration, muscle wasting and death into the second/third decade of life. Beside, BMD patients show a very mild phenotype, often asymptomatic primarily due to the expression of shorter dystrophin mRNA transcripts that maintain the coding reading frame. DMD patients muscles show absence of dystrophin and presence of endomysial fibrosis, small fibers rounded and muscle fiber degeneration/regeneration. Untreated, boys with DMD become progressively weak during their childhood and stop ambulation at a mean age of 9 years, later with corticosteroid treatment (12/13 yrs). Proximal weakness affects symmetrically the lower (such as quadriceps and gluteus) before the upper extremities, with progression to the point of wheelchair dependence. Eventually distal lower and then upper limb weakness occurs. Weakness of neck flexors is often present at the beginning, and most patients with DMD have never been able to jump. Wrist and hand muscles are involved later, allowing the patients to keep their autonomy in transfers using a joystick to guide their wheelchair. Musculoskeletal contractures (ankle, knees and hips) and learning difficulties can complicate the clinical expression of the disease. Besides this weakness distribution in the same patient, a deep variability among patients does exist. They could express a mild phenotype, between Becker and Duchenne dystrophy, or a really severe form, with the loss of deambulation at 7-8 years. Confinement to a wheelchair is followed by the development of scoliosis, respiratory failure and cardiomyopathy. In 90% of people death is directly related to chronic respiratory insufficiency (Rideau et al., 1983). The identification and characterization of dystrophin gene led to the development of potential treatments for this disorder (Bertoni, 2008). Even if only corticosteroids were proven to be effective on DMD patient (Hyser and Mendell, 1988), different therapeutic approaches were attempted, as described in detail below (see section 7).
The identification and characterization of the genes whose mutations caused the most common neuromuscular diseases led to the development of potential treatments for those disorders. Gene therapy for neuromuscular disorders embraced several concepts, including replacing and repairing a defective gene or modifying or enhancing cellular performance, using gene that is not directly related to the underlying defect (Shavlakadze et al., 2004). As an example, the finding that DMD pathology was caused by mutations in the dystrophin gene allowed the rising of different therapeutic approaches including growth-modulating agents that increase muscle regeneration and delay muscle fibrosis (Tinsley et al., 1998), powerful antisense oligonucleotides with exon-skipping capacity (Mc Clorey et al., 2006), anti-inflammatory or second-messenger signal-modulating agents that affect immune responses (Biggar et al., 2006), agents designed to suppress stop codon mutations (Hamed, 2006). Viral and non-viral vectors were used to deliver the full-length - or restricted versions - of the dystrophin gene into stem cells; alternatively, specific antisense oligonucleotides were designed to mask the putative splicing sites of exons in the mutated region of the primary RNA transcript whose removal would re-establish a correct reading frame. In parallel, the biology of stem cells and their role in regeneration were the subject of intensive and extensive research in many laboratories around the world because of the promise of stem cells as therapeutic agents to regenerate tissues damaged by disease or injury (Fuchs and Segre, 2000; Weissman, 2000). This research constituted a significant part of the rapidly developing field of regenerative biology and medicine, and the combination of gene and cell therapy arose as one of the most suitable possibility to treat degenerative disorders. Several works were published in which stem cell were genetically modified by ex vivo introduction of corrective genes and then transplanted in donor dystrophic animal models.
Stem cells received much attention because of their potential use in cell-based therapies for human disease such as leukaemia (Owonikoko et al., 2007), Parkinsons disease (Singh et al., 2007), and neuromuscular disorders (Endo, 2007; Nowak and Davies, 2004). The main advantage of stem cells rather than the other cells of the body is that they can replenish their numbers for long periods through cell division and, they can produce a progeny that can differentiate into multiple cell lineages with specific functions (Bertoni, 2008). The candidate stem cell had to be easy to extract, maintaining the capacity of myogenic conversion when transplanted into the host muscle and also the survival and the subsequent migration from the site of injection to the compromise muscles of the body (Price et al., 2007). With the advent of more sensitive markers, stem cell populations suitable for clinical experiments were found to derive from multiple region of the body at various stage of development. Numerous studies showed that the regenerative capacity of stem cells resided in the environmental microniche and its regulation. This way, it could be important to better elucidate the molecular composition cytokines, growth factors, cell adhesion molecules and extracellular matrix molecules - and interactions of the different microniches that regulate stem cell development (Stocum, 2001).
Several groups published different works concerning adult stem cells such as muscle-derived stem cells (Qu-Petersen et al., 2002), mesoangioblasts (Cossu and Bianco, 2003), blood- (Gavina et al., 2006) and muscle (Benchaouir et al., 2007)-derived CD133+ stem cells. Although some of them are able to migrate through the vasculature (Benchaouir et al., 2007; Galvez et al., 2006; Gavina et al., 2006) and efforts were done to increase their migratory ability (Lafreniere et al., 2006; Torrente et al., 2003a), poor results were obtained.
Embryonic and adult stem cells differ significantly in regard to their differentiation potential and in vitro expansion capability. While adult stem cells constitute a reservoir for tissue regeneration throughout the adult life, they are tissue-specific and possess limited capacity to be expanded ex vivo. Embryonic Stem (ES) cells are derived from the inner cell mass of blastocyst embryos and, by definition, are capable of unlimited in vitro self-renewal and have the ability to differentiate into any cell type of the body (Darabi et al., 2008b). ES cells, together with recently identified iPS cells, are now broadly and extensively studied for their applications in clinical studies.
Embryonic stem cells are pluripotent cells derived from the early embryo that are characterized by the ability to proliferate over prolonged periods of culture remaining undifferentiated and maintaining a stable karyotype (Amit and Itskovitz-Eldor, 2002; Carpenter et al., 2003; Hoffman and Carpenter, 2005). They are capable of differentiating into cells present in all 3 embryonic germ layers, namely ectoderm, mesoderm, and endoderm, and are characterized by self-renewal, immortality, and pluripotency (Strulovici et al., 2007).
hESCs are derived by microsurgical removal of cells from the inner cell mass of a blastocyst stage embryo (Fig. 1). The ES cells can be also obtained from single blastomeres. This technique creates ES cells from a single blastomere directly removed from the embryo bypassing the ethical issue of embryo destruction (Klimanskaya et al., 2006). Although maintaining the viability of the embryo, it has to be determined whether embryonic stem cell lines derived from a single blastomere that does not compromise the embryo can be considered for clinical studies. Cell Nuclear Transfer (SCNT): Nuclear transfer, also referred to as nuclear cloning, denotes the introduction of a nucleus from an adult donor cell into an enucleated oocyte to generate a cloned embryo (Wilmut et al., 2002).
ESCs differentiation. Differentiation potentiality of human embryonic stem cell lines. Human embryonic stem cell pluripotency is evaluated by the ability of the cells to differentiate into different cell types.
Read more:
Stem Cell Therapy for Neuromuscular Diseases | InTechOpen
- CAR T-Cell Immunotherapy for ALL - National Cancer Institute - October 27th, 2015
- Gene Therapy and Cell Therapy Defined | ASGCT - American ... - October 20th, 2015
- StemCell Therapy MD - October 3rd, 2015
- Stem Cell Therapy in Mexico - May 8th, 2015
- Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients - Video - May 1st, 2015
- Platelet Rich Plasma Injections For Chronic Pain Relief May Help You Avoid Sugery - Video - May 1st, 2015
- Stem Cell Treatment for COPD | StemRx Bioscience Solutions - Video - April 25th, 2015
- Stem Cell Therapy Market in Asia-Pacific to 2018 - Video - April 22nd, 2015
- Phytoscience Philipine celebrity Share good effect of stem cell Therapy - Video - April 18th, 2015
- STEM CELL therapy incredible results for severe MS - Video - April 18th, 2015
- Clinical Benefits of Stem Cell Therapy - Video - April 18th, 2015
- NYC Health & Longevity Center Now Offering Stem Cell Therapy to Avoid Joint Replacement - April 13th, 2015
- U.S. Stem Cell Clinic: What Conditions Can Be Treated? - Video - April 12th, 2015
- Stem Cell Therapy In USA - April 12th, 2015
- Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video - April 11th, 2015
- What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How long will my recovery take? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: Stem Cell Banking - Video - April 11th, 2015
- U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: When should I expect to see results? - Video - April 11th, 2015
- Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video - April 3rd, 2015
- Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016 - April 3rd, 2015
- Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy to Help Patients Avoid Hip and Knee Replacement - March 31st, 2015
- Center of Regenerative Orthopedics in South Florida Now Offering Stem Cell Therapy to Help Avoid Hip and Knee ... - March 31st, 2015
- Ask Dr. Lemper | Stem Cell Therapy Treatments - Video - March 29th, 2015
- No stem cell treatment for public servant's dodgy knee - March 26th, 2015
- Stem Cell Therapy - Lilli Donovan - Video - March 25th, 2015
- Stem Cell Research - Stem Cell Treatments - Treatments ... - March 25th, 2015
- What is "Stem cell therapy" ? | Steps in PRP Treatment : TV5 News - Video - March 23rd, 2015
- Stem cell clinics under govt scanner - March 22nd, 2015
- SuperCells at Centre for Life - Video - March 21st, 2015
- Knee arthritis 3 years after stem cell therapy by Harry Adelson, N.D. - Video - March 21st, 2015
- Stem Cell Injection Treatment Stem Cell Therapy - Video - March 21st, 2015
- stem cell therapy di indonesia Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video - March 20th, 2015
- Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video - March 20th, 2015
- Stem cell therapy may help treat type 2 diabetes - March 20th, 2015
- CAR T-Cell Therapy - Nebraska Medicine - Video - March 18th, 2015
- Stem Cell Therapy- Sci Video2 - Video - March 18th, 2015
- Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics - March 17th, 2015
- Stem Cell Research & Therapy | Full text | Amnion-derived ... - March 15th, 2015
- High-Dose Immunosuppressive Therapy and Autologous ... - March 15th, 2015
- Miracle stem cell therapy reverses multiple sclerosis - Video - March 14th, 2015
- Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video - March 13th, 2015
- Stem Cell Therapy Network - Video - March 12th, 2015
- Stem Cell Therapy Cream - Video - March 9th, 2015
- BioLogic Stem Cell Therapy Cream - Video - March 8th, 2015
- World Over - 2015-02-26 - Vatican latest, ISIS, stem cell therapy, Ray Flynn with Raymond Arroyo - Video - March 8th, 2015
- Shoulder Labral Tear Repair Using Stem Cell Therapy - Orthopedic Surgeon, Dr. Wade McKenna - Video - March 6th, 2015
- What Makes Riordan-McKenna Institute Different? Stem Cell Therapy for Orthopedics - Video - March 6th, 2015
- Overcoming Knee Replacement Surgery Faster Using Amniotic Tissue-Enhanced Stem Cell Therapy - Video - March 6th, 2015
- Stem Cell Therapy in Osteo Arthritis Knee - Video - March 6th, 2015
- stem cell therapy helps avoiding knee surgery - Video - March 6th, 2015
- Stem cell therapy in AKI Dr Mohamed Kamal - Video - March 6th, 2015
- Stem Cell Therapy for Bone Fractures - Board-Certified Orhopedic Surgeon, Wade McKenna DO - Video - March 5th, 2015
- Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video - March 1st, 2015
- Animal cells for a younger you - March 1st, 2015
- 'Miracle' stem cell therapy reverses multiple sclerosis - March 1st, 2015
- Stem cell therapy a boon to Parkinson's patients - February 27th, 2015
- Stem Cell Research & Therapy | Full text | Aromatic ... - February 23rd, 2015
- Why Stem Cell Therapy? - Video - February 22nd, 2015
- What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? - Video - February 21st, 2015
- Dr Ellis hosts seminar on Stem Cell Therapy & Facial Rejuvenation - Video - February 17th, 2015
- Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D. - Video - February 16th, 2015
- How about Stem Cell Therapy for LBD, Nova Cells Institute stem cells - Video - February 14th, 2015
- Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital - Video - February 14th, 2015
- Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? - February 10th, 2015
- International Stem Cell completes cell bank manufacturing for Parkinson's disease clinical trial - February 4th, 2015
- Tampa stem cell clinic is long on promises, not evidence - February 1st, 2015
- Denver Regenerative Medicine - What is regenerative medicine? - Video - January 30th, 2015
- Cell Trials - January 26th, 2015
- "She's Happy" RMG's next Stem Cell Miracle - Video - January 21st, 2015
- Nutech Mediworld - Pioneering human embryonic stem cell therapy - Video - January 21st, 2015
- Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video - January 20th, 2015
- Dr Sherif Stem cell therapy on OA - Video - January 18th, 2015
- Live100 Hospitals - Stem Cell Therapy - Video - January 16th, 2015
- How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video - January 16th, 2015